Introduction
============

T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL) is a rare subtype of diffuse large B-cell lymphoma (DLBCL) characterized by a low fraction of tumor B cells and a cellular background rich in T cells and histiocytes. It has been classified as a separate entity of mature B-cell lymphoma since the fourth edition of the World Health Organization (WHO) classification of lymphoid neoplasms.^[@b1-1040330],[@b2-1040330]^ Although it has a more aggressive clinical behavior and distinct microenvironmental composition,^[@b3-1040330],[@b4-1040330]^ THRLBCL shares several clinical and pathological features with nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL), a rare subtype of Hodgkin lymphoma. The similarities include a predominance of middle-aged male patients^[@b5-1040330]^ and a minority of tumor cells derived from germinal center B cells in an abundant microenvironment.^[@b6-1040330],[@b7-1040330]^ Furthermore, a high similarity of gene expression signatures^[@b4-1040330],[@b8-1040330]^ and genomic copy number changes in the microdissected tumor cells of NLPHL and THRLBCL were found.^[@b9-1040330]^ According to Fan *et al*.,^[@b10-1040330]^ NLPHL can be subdivided into six different histopathological patterns, which include two typical nodular growth patterns (A and B) and four histopathological variants (C-F). The NLPHL variant E, also called THRLBCL-like variant, shows particularly marked similarities with THRLBCL and can only be distinguished from *de novo* THRLBCL by the presence of typical NLPHL remnants in the same lymph node or in another lymph node simultaneously sampled. In general, histopathological NLPHL variants are associated with an advanced clinical stage and an increased relapse rate.^[@b10-1040330],[@b11-1040330]^

Data on somatic gene mutations of the tumor cells of THRLBCL are still lacking. Hence, we aimed to elucidate the relationship of THRLBCL and NLPHL through a comparison of recurrently mutated genes to obtain a more comprehensive understanding of the pathogenesis of THRLBCL.

Methods
=======

Cases
-----

Cases were collected based on the availability of frozen tissue at the Dr. Senckenberg Institute of Pathology, Frankfurt am Main, Germany; the Department of Pathology University Hospitals, K.U. Leuven, Belgium; the Unit of Lymphoid Malignancies, San Raffaele Scientific Institute, Milan, Italy; Tampere University Hospital and University of Tampere, Tampere, Finland; and the Department of Pathology and Laboratory Medicine and the Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, Canada. The local ethics committees approved the study, and written informed consent from the donors was obtained in accordance with the Declaration of Helsinki. All cases were reviewed on a multi-head microscope by expert hematopathologists (RG, SH, MLH, and TT). Only cases meeting the diagnostic criteria of the current WHO classification for NLPHL and THRLBCL^[@b1-1040330],[@b2-1040330]^ were included in the study. Coexisting NLPHL was not found in any of the THRLBCL cases. For correlative analysis, NLPHL cases were classified according to Fan *et al*.^[@b10-1040330]^ For this purpose, the major pattern present in the frozen sample was considered. In all cases, the initial biopsies before treatment were analyzed. All cases also presented a typical immunopheno-type of the tumor cells (CD20^+^, BCL6^+^, OCT2^+^, CD30^−^, CD15^−^, LMP1^−^). Information on the patients is provided in [Table 1](#t1-1040330){ref-type="table"}.
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Clinical information on nodular lymphocyte-predominant Hodgkin lymphoma and T-cell/histiocyte-rich large B-cell lymphoma patients.
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Ultra-deep targeted resequencing and identification of somatic variants
-----------------------------------------------------------------------

Extraction of genomic DNA from frozen tissue of cases of THRLBCL and NLPHL, ultra-deep targeted resequencing after bait-based enrichment by a custom Haloplex kit (Agilent, Santa Clara, CA, USA) and processing of sequencing reads were carried out as described previously.^[@b12-1040330]^ All 62 genes used for the ultra-deep targeted resequencing were selected based on mutated genes from a previous study of two clonally related composite lymphomas consisting of NLPHL and DLBCL (*Online Supplementary Table S1*).^[@b12-1040330]^ Some of these selected genes were already confirmed to be mutated in primary NLPHL without transformation into DLBCL.^[@b12-1040330]^ The mean coverage of the 26 cases ranged between 3500 and 8500× (*Online Supplementary Table S2*). Non-synonymous single nucleotide variants (SNVs) were filtered for allele frequencies based on the expected tumor cell content (0.1-10%), and the presence and somatic origin of selected variants were confirmed in a semi-nested polymerase chain reaction (PCR) approach followed by Sanger sequencing of the PCR products, as indicated in *Online Supplementary Table S3*. Details on validation of mutations using microdissected tumor cells and analysis of the somatic hypermutation (SHM) features of SNVs are provided in the *Online Supplementary Methods* section.

Laser microdissection and Immunohistochemistry
----------------------------------------------

Frozen sections (5 - 10 μm) of lymph nodes from lymphoma patients were mounted on membrane-covered slides (PALM, Zeiss, Bernried, Germany), then air-dried and fixed in acetone. Sections were stained with a mouse monoclonal anti-CD20 antibody (clone L26, Dako, Glostrup, Denmark) in 1:200 dilution for 1 h at room temperature. Binding of the primary antibody was visualized with the aid of the Super Sensitive™ Link-Label IHC Detection System (BioGenex, Fremont, CA, USA), and counter-staining with hematoxylin was performed. For PCR analysis, 20 single tumor cells and non-tumor cells were isolated using the PALM laser capture microdissection technique (PALM MicroBeam, Zeiss, Bernried, Germany) and collected in 20 μL PCR buffer without MgCl~2~ (Expand High Fidelity, Roche, Grenzach, Germany) supplemented with 0.1% Triton X-100.

The immunohistochemical staining for activation-induced cytidine deaminase (AICDA) was performed on an independent series of 15 typical and 11 variant NLPHL as well as 12 THRLBCL with formalin-fixed paraffin-embedded tissue as previously described.^[@b13-1040330]^ The anti-AICDA antibody (clone EK2 5G9, Cell Signaling, Danvers, MA, USA) was applied in a dilution of 1:100.

Results
=======

T-cell/histiocyte-rich large B-cell lymphoma shares recurrently mutated genes with nodular lymphocyte-predominant Hodgkin lymphoma
----------------------------------------------------------------------------------------------------------------------------------

Ultra-deep targeted resequencing of the coding exons of 62 genes (*Online Supplementary Table S1*), which were found to be mutated in NLPHL in a previous study,^[@b12-1040330]^ was performed in the following three groups: THRLBCL (n=9); typical NLPHL, patterns A/B (n=6); and histopathological NLPHL variants, patterns C/D/E (n=11), yielding a total number of 26 cases. The patients' characteristics are given in [Table 1](#t1-1040330){ref-type="table"}. The coding exons of selected genes were analyzed for non-synonymous SNVs in order to identify mutations with a potential functional effect.

Of the 62 NLPHL-related genes, 48 (77%) were somatically mutated in at least one of the 26 cases (*Online Supplementary Table S3*). A total of 33 genes (53%) were recurrently affected by mutations in at least two cases ([Figure 1A](#f1-1040330){ref-type="fig"}). Specifically in THRLBCL, 31 genes (50%) were mutated, and 13 of these showed recurrent mutations in at least two cases, indicating a considerable mutational overlap between THRLBCL and NLPHL. The genes with the highest overall mutation frequency (ε20% of all 26 cases) were *JUNB*, *DUSP2*, *SGK1*, *SOCS1*, *CREBBP*, *FN1* and *TRRAP* ([Figure 1A](#f1-1040330){ref-type="fig"}). Mutation frequencies in *JUNB*, *SGK1*, *CREBBP* and *TRRAP* were higher, albeit not significantly so, in both THRLBCL and the NLPHL variants C/D/E than in typical NLPHL A/B ([Figure 1A](#f1-1040330){ref-type="fig"}).

![Genes recurrently affected by mutations and their mutational load in nodular lymphocyte-predominant Hodgkin lymphoma and T-cell/histiocyte-rich large B-cell lymphoma. (A) Frequencies of recurrently mutated genes (≥2 cases) in six cases of NLPHL A/B (blue), 11 cases of NLPHL C/D/E (green) and nine cases of THRLBCL (red) sorted by overall recurrence. (B) Mutated genes per case in NLPHL A/B, NLPHL C/D/E and THRLBCL. (C) Number of SNVs per case in NLPHL A/B, NLPHL C/D/E and THRLBCL. (D) Scatter plot of SNVs per case and kbp of CCDS in the seven most recurrently mutated genes in NLPHL A/B, NLPHL C/D/E and THRL-BCL. In (B-D), horizontal lines correspond to medians; *P*-values by Kruskal-Wallis test are indicated in the case of statistical significance. \**P*\<0.05, \*\**P*\<0.01, \*\*\**P*\<0.001. NLPHL: nodular lymphocyte-predominant Hodgkin lymphoma; THRLBCL: T-cell/histiocyte-rich large B-cell lymphoma; SNVs: single nucleotide variants; CCDS: Consensus coding sequence.](104330.fig1){#f1-1040330}

The median number of mutated genes per case was comparable between typical NLPHL (median 3.5; range, 2-13), histopathological NLPHL variants C/D/E (median 5.0; range, 1-11) and THRLBCL (median 4.0; range, 2-20) ([Figure 1B](#f1-1040330){ref-type="fig"}). However, the median number of SNVs per case was slightly increased in THRLBCL (median 12; range, 2-30) when compared with that in typical NLPHL (median 7; range, 2-14) and NLPHL variants C/D/E (median 8; range, 1-20) ([Figure 1C](#f1-1040330){ref-type="fig"}). Notably, the number of SNVs per case was specifically increased in the four genes *JUNB*, *DUSP2*, *SGK1* and *SOCS1* (1-5 SNVs/case) when compared to *CREBBP*, *FN1* and *TRRAP* (1-2 SNVs/case), particularly in regard to the shorter coding sequence of the first four genes (\<1.3 kb *versus* \>7.3 kb) ([Figure 1D](#f1-1040330){ref-type="fig"}). The higher number of SNVs per case found in THRLBCL was, therefore, related to the higher number of SNVs in these four genes.

*SOCS1* was the only gene in which mutations occurred significantly more frequently in THRLBCL than in typical NLPHL A/B (4/9 cases *versus* 0/6 cases, respectively; *P*=0.010, χ^2^-test) and in NLPHL in general (4/9 cases *versus* 3/17 cases, respectively; *P*=0.035, χ^2^-test).

Furthermore, the number of SNVs per case was significantly increased in *SOCS1* in THRLBCL (median 5.0; range, 3-6) when compared with that in histopathological NLPHL variants C/D/E (median 1.5; range, 1-2; *P*=0.048, Mann-Whitney test). *JUNB* was the gene with the highest number of nonsense mutations, which were present in both NLPHL (2/15 mutations) and THRLBCL (2/12 mutations).

The genes with the highest mutation frequency are targets of aberrant somatic hypermutation
-------------------------------------------------------------------------------------------

Regarding the distribution of mutations in the seven most recurrently mutated genes, SNVs were generally distributed throughout the coding sequence with no difference in the mutational distribution between the three groups of lymphoma ([Figure 2](#f2-1040330){ref-type="fig"}). Protein domains with functional relevance were affected by mutations, e.g. the SH2 domain of the negative regulator of JAK-STAT signaling SOCS1, the catalytic domain of the protein kinase SGK1 and the histone acetyltransferase domain of the chromatin modifier CREBBP, suggesting that mutations in these genes result in an alteration of the protein function. In the three relatively small genes (\<2.5 kb) *JUNB*, *DUSP2* and *SOCS1*, SNVs clustered to specific regions in the coding sequence with an enrichment to the first 150 bp downstream of the start codon in *JUNB*, to exon 2 in *DUSP2* and to the first 80 bp of the coding sequence in *SOCS1*. In *CREBBP*, *FN1* and *TRRAP*, which were the three larger genes (\>75 kb), mutations tended to be diffusely scattered and localized further downstream of the transcriptional start site. Given the fact of ongoing SHM in NLPHL and THRLBCL,^[@b6-1040330],[@b7-1040330]^ as well as aberrant activity of the SHM machinery in these entities,^[@b14-1040330]^ we explored whether mutations in the most recurrently mutated genes were caused by aberrant SHM. Criteria of SHM activity were investigated, as previously described in other reports.^[@b14-1040330]--[@b17-1040330]^ Mutations in the genes *JUNB*, *DUSP2*, *SGK1* and *SOCS1* were highly enriched in SHM hotspot sites ([Figure 3A](#f3-1040330){ref-type="fig"}) and also met other SHM criteria in most SNVs ([Figure 3B,C](#f3-1040330){ref-type="fig"}). Mutations in *CREBBP*, *FN1* and *TRRAP* occasionally occurred at C:G sites and showed a predominance of transitions over transversions ([Figure 3B,C](#f3-1040330){ref-type="fig"}). However, they were clearly located outside the SHM hotspot motifs WR[C]{.ul}Y/R[G]{.ul}YW ([Figure 3A](#f3-1040330){ref-type="fig"}). In line with these results of an active SHM machinery and consistent with previous data,^[@b13-1040330],[@b18-1040330]^ expression of AICDA could be demonstrated in the tumor cells of typical and histopathological NLPHL variants (10/15 and 3/11 cases, respectively) ([Figure 3D](#f3-1040330){ref-type="fig"}) as well as THRLBCL (10/12 cases) ([Figure 3E](#f3-1040330){ref-type="fig"}) in an independent case series.

![Mutation patterns in the most recurrently mutated genes in nodular lymphocyte-predominant Hodgkin lymphoma and T-cell/histiocyte-rich large B-cell lymphoma. Schematic overview of the mutational distribution in the most recurrently mutated genes. For each gene missense (triangles), stop gain (spheres) and splice site (squares) mutations are mapped to coding exons (top) and protein domains (bottom). Mutations are color-coded according to the occurrence in the groups (blue: NLPHL A/B; green: NLPHL C/D/E; red: THRLBCL). Amino acid positions of protein domains are adopted from the Uniprot database ([www.uniprot.org](www.uniprot.org)) and refer to the canonical sequences (JUNB: P17275, DUSP2: Q05923, SGK1: O00141, SOCS1: O15524, CREBBP: Q92793, FN1: P02751, TRRAP: Q9Y4A5). bZIP: basic leucine zipper motif; DsPc: dual specific phosphatase, catalytic domain; Pkinase: protein kinase domain; AGC-kinase C: AGC-kinase C-terminal domain; Rhod: rhodanese; SH2: Src homology 2 domain; KIR: kinase inhibitory region; CH1/2/3: cysteine/hystidine-rich region; KIX: kinase inducible domain; BROMO: bromodomain; HAT: histone acetyltransferase domain; Q: poly glutamine stretch; FN: fibronectin; TP53: tumor suppressor p53 binding site; FAT: FRAP-ATM-TRRAP domain; FATC: FAT C-terminal; PI3K/PI4K: phosphatidylinositol 3-kinase/phosphatidylinositol 4-kinase domain; NLPHL: nodular lymphocyte-predominant Hodgkin lymphoma; THRLBCL: T-cell/histiocyte-rich large B-cell lymphoma.](104330.fig2){#f2-1040330}

![Characteristics of somatic mutations and activation-induced cytidine deaminase expression in nodular lymphocyte-predominant Hodgkin lymphoma and T-cell/histiocyte-rich large B-cell lymphoma. (A) Analysis of distribution of mutations to SHM hotspot motifs. (B) Ratio of mutations at C:G sites to A:T sites. (C) Ratio of transition to transversion mutations. In (A-C) synonymous SNVs were considered in addition to non-synonymous SNVs. Asterisks denote statistical significance. \**P*\<0.05, \*\**P*\<0.01, \*\*\**P*\<0.001. *P*-values by χ^2^ test. (D) Expression of AICDA in the LP cells of NLPHL (400× magnification). (E) Expression of AICDA in the tumor cells of THRLBCL (400× magnification). Tumor cells are highlighted by arrows. AICDA: activation-induced cytidine deaminase; NLPHL: nodular lymphocyte-predominant Hodgkin lymphoma; THRLBCL: T-cell/histiocyte-rich large B-cell lymphoma; SHM: somatic hypermutation; SNVs: single nucleotide variants.](104330.fig3){#f3-1040330}

Discussion
==========

In the present study, we performed ultra-deep targeted resequencing of a set of genes that had been previously identified to be mutated in two cases of composite lymphoma of NLPHL with transformation into DLBCL.^[@b12-1040330]^ Four of these target genes, namely *JUNB*, *DUSP2*, *SGK1* and *SOCS1*, were also found to be mutated in primary NLPHL cases without transformation. Since the relationship of NLPHL and THRLBCL has been long-discussed, we aimed to determine whether these four genes, among others, are also mutated in THRLBCL. Here, we confirm that mutations in these genes also occur at comparable frequencies in THRLBCL.

*SGK1* and *SOCS1* are frequently mutated in germinal center B-cell (GCB)-derived lymphomas such as follicular lymphoma and GCB-type DLBCL.^[@b18-1040330]--[@b21-1040330]^ *DUSP2* is less frequently mutated in malignant lymphomas; however, *DUSP2* mutations have been described in DLBCL,^[@b15-1040330],[@b22-1040330],[@b23-1040330]^ primary mediastinal B-cell lymphoma^[@b24-1040330]^ and chronic lymphocytic leukemia.^[@b25-1040330]^ In contrast, to date, *JUNB* has been reported, to our knowledge, to be relatively specifically mutated in NLPHL.^[@b12-1040330]^ The total percentage of samples of hematopoietic and lymphoid neoplasms with mutations in *JUNB* in the COSMIC database (*<https://cancer.sanger.ac.uk/cosmic>*) is 0.09% (3 of 3516 samples tested). Two of these cases had non-synonymous mutations: one DLBCL and one lymphoid neoplasm not otherwise specified (COSMIC ID COSS2121012). The third case, a cutaneous T-cell lymphoma of mycosis fungoides type,^[@b26-1040330]^ presented a synonymous *JUNB* mutation. In the whole exome sequencing study on classical Hodgkin lymphoma by Tiacci *et al*.^[@b27-1040330]^, only one of 34 cases presented a non-synonymous *JUNB* mutation. Therefore, the high frequency of non-synonymous *JUNB* mutations, including a relatively frequent occurrence of *JUNB* nonsense mutations in both NLPHL and THRLBCL, is a hallmark of these lymphoma entities.

Mutations in the four genes *JUNB*, *DUSP2*, *SGK1* and *SOCS1* were more frequent in THRLBCL and the histopathological NLPHL variants than in typical NLPHL. Since we performed ultra-deep targeted resequencing of whole tissue DNA and allowed allele frequencies of mutations to range within the expected tumor cell content (0.1-10%), this approach might more sensitively identify sub-clonal variants in THRLBCL than in NLPHL due to the slightly higher tumor cell content in THRLBCL compared to NLPHL (median 10% *versus* 3%). However, the tumor cell content did not differ significantly between histopathological NLPHL variants and typical NLPHL (3% *versus* 2%, respectively) and thus does not explain the higher number of mutations in histopathological NLPHL variants than in typical NLPHL.

*SOCS1* is a known target of aberrant SHM,^[@b18-1040330]^ and SHM of immunoglobulin genes is known to be ongoing in the tumor cells of NLPHL and THRLBCL.^[@b6-1040330],[@b7-1040330],[@b14-1040330]^ The mutation patterns of *JUNB*, *SGK1*, *DUSP2* and *SOCS1* observed in the tumor cells of NLPHL and THRLBCL suggest that mutations in these four genes are most likely the result of aberrant SHM, which is likely contributing importantly to the development of these lymphomas. The genes *DUSP2* and *SGK1* were previously identified as potential targets of aberrant SHM in GCB-type DLBCL,^[@b15-1040330]^ but are less frequently mutated in GCB-type DLBCL than in NLPHL and THRLBCL. SHM activity is reported to start closely downstream from the transcriptional start site extending up to 2 kb into the gene,^[@b28-1040330]^ which is in line with an enrichment of SNVs in SHM hotspot motifs in the three relatively small genes *JUNB*, *DUSP2* and *SOCS1* (\<2.5 kb). The more frequent occurrence of SNVs in SHM hotspot sites in THRL-BCL and histopathological NLPHL variants might be related to a longer and/or stronger exposure of the tumor cells to the SHM machinery. Aberrant activity of the SHM machinery may be caused by loss of target specificity and lead to insertion of mutations into genomic regions showing active transcription and a favorable epigenetic environment.^[@b15-1040330],[@b29-1040330],[@b30-1040330]^ This might also contribute to the more aggressive clinical behavior of these entities if a high rate of aberrant SHM affects further target genes that were not profiled here.

According to our data, *SOCS1*, previously shown to be mutated in NLPHL,^[@b12-1040330],[@b31-1040330]^ was mutated in both histopathological NLPHL variants and THRLBCL. *SOCS1* was not mutated in the typical NLPHL cases of this study, as observed previously.^[@b12-1040330]^ This is likely related to the low number of typical NLPHL cases investigated. On the other hand, one may speculate that *SOCS1* may act as a potential driver gene indicating disease progression and may thus represent a progression driver. However, the histopathological growth patterns of the NLPHL cases investigated were not considered in the study by Mottok *et al*.^[@b31-1040330]^ Despite the fact that typical NLPHL represents the majority of NLPHL cases, in our experience most frozen NLPHL samples are acquired from histopathological NLPHL variants. One reason for this may be because the patients with histopathological NLPHL variants present with more advanced disease and are more likely to present in a specialized medical center where frozen tissue can be preserved. A potential role of *SOCS1* as a driver towards disease progression is further supported by previous reports, in which *SOCS1* missense mutations were found to be related to a more aggressive clinical behavior in a cohort of DLBCL cases treated with CHOP-like regimens.^[@b32-1040330]^ The prognostic impact of *SOCS1* mutations should therefore be investigated in a larger cohort of NLPHL. Moreover, as the ultra-deep targeted sequencing approach used here is not very reliable in the identification of structural variants, these were not considered here. Given that a high number of *SOCS1* aberrations have been reported to be insertions/deletions^[@b31-1040330],[@b32-1040330]^ we, therefore, likely underestimate the frequency of *SOCS1* mutations.

Mutations in the acetyltransferase *CREBBP* were usually not a result of aberrant SHM. They frequently affected the KIX domain that mediates binding to transcription factors,^[@b33-1040330]^ the HAT domain that performs histone acetyltransferase activity and the C-terminal Q-rich domain, which is part of a transactivation domain,^[@b33-1040330]^ consistent with the functional consequences reported for DLBCL and follicular lymphoma.^[@b34-1040330]^ Notably, two mutations in the HAT domain of *CREBBP* detected in DLBCL (nonsense R1341X and R1360X)^[@b34-1040330]^ also occurred at the same residue in a patient with NLPHL variant pattern E (R1341X) and a patient with THRLBCL (R1360P), suggesting that the HAT domain is under inactivating pressure in these GCB-cell derived malignancies. Thus, in addition to aberrant SHM, further transforming events are likely required for the development of NLPHL and THRLBCL.

Since the gene panel applied in the present study was based on genes previously identified in composite lymphomas of NLPHL and DLBCL, we were not in a position to identify novel genes that are recurrently mutated in THRLBCL but not or only rarely in NLPHL. This is a clear limitation of our study. Thus, genome-wide mutation studies are warranted to comprehensively determine the mutational landscape of THRLBCL. Nevertheless, the fact that the most frequently mutated genes in NLPHL are also recurrently mutated in THRLBCL makes a strong point regarding the close relationship of these malignancies, which had been proposed in earlier studies based on histopathological features, related gene expression profiles, and similar genomic imbalances.^[@b4-1040330],[@b8-1040330],[@b9-1040330]^ Perhaps *de novo* THRLBCL could principally represent a transformation from NLPHL, and thus share key mutations that were acquired in the earlier NLPHL lymphomagenesis. Considering the clinical presentation of the patients, one could speculate that typical and histopathological NLPHL variants have a similar relationship to THRLBCL, as is observed in follicular lymphoma grade 1/2 to 3a and transformation into DLBCL.
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